HDAC9 and cancer: Any treatments that disrupt the complex of P-TEFb with 7SK-snRP, including other cancer drugs, such as HDAC inhibitors and azacytidine (Fujinaga et al., 2015), could potentially cause transcription-replication conflicts in this way.